Yahoo
NYSE - Nasdaq Real Time Price USD

Revvity, Inc. (RVTY)

165.51 +0.18 (+0.11%)
As of 10:00:10 AM EDT. Market Open.
Trade Revvity on Coinbase
Chart Range Bar
Loading chart for RVTY

What's happening with RVTY?

13m ago
Powered by Yahoo Scout

Revvity enters its November 3, 2026 earnings reportwith a record of recent earnings beats, although revenue growth expectations remain modest. The company is also preparing to launch Signals LabGistics, an AI-enabled workflow platform, while valuation concerns remain after a strong share-price rally.

Powered by Yahoo Scout
  • Previous Close 165.33
  • Open 165.32
  • Bid 164.25 x 10000
  • Ask 165.61 x 10000
  • Day's Range 163.05 - 166.32
  • 52 Week Range 81.22 - 169.06
  • Volume 80,822
  • Avg. Volume 1,833,015
  • Market Cap (intraday) 18.469B
  • Beta (5Y Monthly) 1.06
  • PE Ratio (TTM) 79.19
  • EPS (TTM) 2.09
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield 0.28 (0.17%)
  • 1y Target Est 147.53
  • Morningstar Rating Rating available with Stock Picks access

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

www.revvity.com

11,000

Full Time Employees

December 28

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RVTY
71.49%
S&P 500 (^GSPC)
12.69%

1-Year Return

RVTY
74.10%
S&P 500 (^GSPC)
11.95%

3-Year Return

RVTY
70.45%
S&P 500 (^GSPC)
87.35%

5-Year Return

RVTY
5.30%
S&P 500 (^GSPC)
67.50%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 711.11M
Earnings 56.82M
Profit Margin 7.99%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
6.0%
8.0%
10.0%
12.0%

Analyst Insights

View More

Analyst Price Targets

110.00 Low
147.53 Average
165.51 Current
175.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 130 -> 175

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.16%

  • Return on Assets (ttm)

    2.37%

  • Return on Equity (ttm)

    3.21%

  • Revenue (ttm)

    2.91B

  • Net Income Avi to Common (ttm)

    237.37M

  • Diluted EPS (ttm)

    2.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.02B

  • Total Debt/Equity (mrq)

    46.22%

  • Levered Free Cash Flow (ttm)

    604.99M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: